Current Atherosclerosis Reports

, Volume 11, Issue 1, pp 64–66

A review of trials evaluating nonstatin lipid-lowering therapies



Recently reported clinical trials raise doubts on the effectiveness of nonstatin lipid-lowering therapies in reducing the residual risk of cardiovascular events after statin monotherapy. Addition of torcetrapib to statin therapy increased overall mortality in coronary patients despite a marked increase in high-density lipoprotein cholesterol. Combining ezetimibe with statin therapy neither further reduces carotid atherosclerosis nor slows aortic stenosis, and it has not been shown to be superior to statin monotherapy in reducing cardiovascular events. Clinical trials currently in progress will more clearly delineate the cardiovascular effects of adding either ezetimibe or extended-release niacin/laropiprant to statin therapy.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Current Medicine Group LLC 2009

Authors and Affiliations

  1. 1.Atherosclerosis Research Unit, Division of Cardiology, Department of MedicineDavid Geffen School of Medicine at UCLALos AngelesUSA

Personalised recommendations